Evidence map›Paper›PMID 38996040›Full record

ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2024

Comprehensive Review on the Use of Oral Cholera Vaccine (OCV) in Ethiopia: 2019 to 2023.

Moti Edosa, Yeonji Jeon, Abel Gedefaw, Dejene Hailu, Edlawit Mesfin Getachew, Ondari D Mogeni, Geun Hyeog Jang, David Mukasa, Biruk Yeshitela, Tomas Getahun and 7 more

Abstract readReview
In one paragraph

Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Coverage of Two-Dose Preemptive Cholera Mass Vaccination Campaign in High-Priority Hotspots in Shashemene, Oromia Region, Ethiopia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  3. Ethiopia National Cholera Elimination Plan 2022-2028: Experiences, Challenges, and the Way Forward.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Moti EdosaPublic Health Emergency Management, Ethiopia Public Health Institute, Addis Ababa, Ethiopia.
Yeonji JeonClinical, Assessment, Regulatory, Evaluation (CARE) Unit, International Vaccine Institute, Seoul, Republic of Korea.ORCID 0009-0006-1728-3627
Abel GedefawClinical, Assessment, Regulatory, Evaluation (CARE) Unit, International Vaccine Institute, Seoul, Republic of Korea.
Dejene HailuClinical, Assessment, Regulatory, Evaluation (CARE) Unit, International Vaccine Institute, Seoul, Republic of Korea.
Edlawit Mesfin GetachewClinical Trials Directorate, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Ondari D MogeniClinical, Assessment, Regulatory, Evaluation (CARE) Unit, International Vaccine Institute, Seoul, Republic of Korea.
Geun Hyeog JangBiostatistics and Data Management (BDM) Department, International Vaccine Institute, Seoul, Republic of Korea.
David MukasaBiostatistics and Data Management (BDM) Department, International Vaccine Institute, Seoul, Republic of Korea.
Biruk YeshitelaBacterial and Viral Disease Research Directorate, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Tomas GetahunClinical Trials Directorate, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Julia LynchCholera Program Director, International Vaccine Institute, Seoul, Republic of Korea.
Malika BouheniaGlobal Task Force on Cholera Control (GTFCC), World Health Organization (WHO), Geneva, Switzerland.
Yeshambel Worku DemliePublic Health Emergency Management, Ethiopia Public Health Institute, Addis Ababa, Ethiopia.
Mukemil HussenPublic Health Emergency Management, Ethiopia Public Health Institute, Addis Ababa, Ethiopia.
Mesfin WossenPublic Health Emergency Management, Ethiopia Public Health Institute, Addis Ababa, Ethiopia.
Mekonnen TeferiClinical Trials Directorate, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Se Eun ParkClinical, Assessment, Regulatory, Evaluation (CARE) Unit, International Vaccine Institute, Seoul, Republic of Korea.ORCID 0000-0002-1632-3045

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundCholera outbreaks in Ethiopia necessitate frequent mass oral cholera vaccine (OCV) campaigns. Despite this, there is a notable absence of a comprehensive summary of these campaigns. Understanding national OCV vaccination history is essential to design appropriate and effective cholera control strategies. Here, we aimed to retrospectively review all OCV vaccination campaigns conducted across Ethiopia between 2019 and 2023.

methodsThe OCV request records from 2019 to October 2023 and vaccination campaign reports for the period from 2019 to December 2023 were retrospectively accessed from the Ethiopia Public Health Institute (EPHI) database. Descriptive analysis was conducted using the retrospective data collected.

resultsFrom 2019 to October 2023, Ethiopian government requested 32 044 576 OCV doses (31 899 576 doses to global stockpile; 145 000 doses to outside of stockpile). Around 66.3% of requested doses were approved; of which 90.4% were received. Fifteen OCV campaigns (12 reactive and 3 pre-emptive) were conducted, including five two-dose campaigns with varying dose intervals and single-dose campaigns partially in 2019 and entirely in 2021, 2022 and 2023. Overall vaccine administrative coverage was high; except for Tigray region (41.8% in the 1st round; 2nd round didn't occur). The vaccine administrative coverage records were documented, but no OCV coverage survey data was available.

conclusionsThis study represents the first comprehensive review of OCV campaigns in Ethiopia spanning the last five years. Its findings offer valuable insights into informing future cholera control strategies, underscoring the importance of monitoring and evaluation despite resource constraints. Addressing the limitations in coverage survey data availability is crucial for enhancing the efficacy of future campaigns.

Indexed as

CholeraCholera VaccinesDisease OutbreaksAdministration, OralEthiopiaHumansImmunization ProgramsMass VaccinationRetrospective StudiesVaccinationCholera VaccinesCholeraEthiopiaglobal OCV stockpileOCVOCV dosing schedules

Identifiers

PMID38996040
PMCPMC11244176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.